Omnicell, Inc. (NASDAQ:OMCL) Stock Has Consensus Target Price of $57.86 According to Brokerages

Shares of Omnicell, Inc. (NASDAQ:OMCL) have been assigned an average recommendation of “Buy” from the nine analysts that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $57.86.

OMCL has been the topic of several analyst reports. Zacks Research raised shares of Omnicell from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 4th. Wall Street Zen cut Omnicell from a “strong-buy” rating to a “buy” rating in a research report on Saturday. KeyCorp reaffirmed an “overweight” rating on shares of Omnicell in a research report on Monday, August 24th. Wells Fargo & Company decreased their price target on Omnicell from $55.00 to $50.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. Finally, Piper Sandler reissued an “overweight” rating and set a $45.00 price objective (down from $55.00) on shares of Omnicell in a report on Monday, August 3rd.

Institutional Investors Weigh In On Omnicell

Large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new stake in Omnicell in the 2nd quarter valued at $313,044,000. Dimensional Fund Advisors LP boosted its holdings in shares of Omnicell by 6.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,450,385 shares of the company’s stock worth $81,791,000 after acquiring an additional 137,834 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its holdings in shares of Omnicell by 2.0% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,410,865 shares of the company’s stock worth $47,095,000 after acquiring an additional 27,497 shares in the last quarter. Bank of America Corp DE increased its stake in shares of Omnicell by 31.3% in the first quarter. Bank of America Corp DE now owns 580,875 shares of the company’s stock valued at $19,390,000 after buying an additional 138,537 shares in the last quarter. Finally, Boston Partners lifted its position in Omnicell by 3.8% during the 3rd quarter. Boston Partners now owns 537,720 shares of the company’s stock worth $18,429,000 after buying an additional 19,561 shares in the last quarter. Institutional investors own 97.70% of the company’s stock.

Omnicell Price Performance

NASDAQ OMCL opened at $35.90 on Wednesday. The company has a quick ratio of 1.45, a current ratio of 1.65 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $1.65 billion, a PE ratio of 23.64, a price-to-earnings-growth ratio of 0.93 and a beta of 0.88. Omnicell has a 12-month low of $31.75 and a 12-month high of $55.00. The company has a 50 day moving average price of $35.03 and a two-hundred day moving average price of $38.64.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Thursday, October 29th. The company reported $0.58 EPS for the quarter, topping the consensus estimate of $0.42 by $0.16. The company had revenue of $307.85 million for the quarter, compared to analyst estimates of $304.44 million. Omnicell had a net margin of 3.59% and a return on equity of 5.69%. Omnicell’s quarterly revenue was down .9% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.51 EPS. As a group, equities analysts predict that Omnicell will post 1.64 earnings per share for the current fiscal year.

About Omnicell

Omnicell, Inc. develops medication-management solutions for healthcare providers. Its products and services are designed to help manage medication storage, dispensing, inventory and workflows across healthcare settings. The company offers automated dispensing cabinets for patient-care areas, automation systems for central pharmacies, and software and analytics that support medication management. Its solutions serve hospitals, health systems, pharmacies and other care providers, including long-term and post-acute care organizations.